MX2015012060A - Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional. - Google Patents
Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional.Info
- Publication number
- MX2015012060A MX2015012060A MX2015012060A MX2015012060A MX2015012060A MX 2015012060 A MX2015012060 A MX 2015012060A MX 2015012060 A MX2015012060 A MX 2015012060A MX 2015012060 A MX2015012060 A MX 2015012060A MX 2015012060 A MX2015012060 A MX 2015012060A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- solid dosage
- immediate release
- abuse deterrent
- functional score
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
La presente descripción proporciona una forma de dosificación sólida farmacéutica disuasiva del abuso y de liberación inmediata que comprende al menos una marca funcional. En particular, la forma de dosificación sólida farmacéutica disuasiva del abuso y de liberación inmediata comprende al menos un polímero hidrofílico de bajo peso molecular, al menos un polímero hidrofílico de alto peso molecular, y un sistema efervescente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792951P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027176 WO2014152296A1 (en) | 2013-03-15 | 2014-03-14 | Abuse deterrent solid dosage form for immediate release with functional score |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015012060A true MX2015012060A (es) | 2016-01-12 |
MX363844B MX363844B (es) | 2019-04-05 |
Family
ID=50686155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012060A MX363844B (es) | 2013-03-15 | 2014-03-14 | Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9301918B2 (es) |
EP (1) | EP2968182B8 (es) |
JP (1) | JP6255474B2 (es) |
BR (1) | BR112015021002B8 (es) |
CA (1) | CA2901802C (es) |
ES (1) | ES2681952T3 (es) |
IL (1) | IL240914B (es) |
MX (1) | MX363844B (es) |
PL (1) | PL2968182T3 (es) |
WO (1) | WO2014152296A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
US11517521B2 (en) | 2014-07-03 | 2022-12-06 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2360102T3 (es) | 2003-03-26 | 2011-05-31 | Egalet A/S | Sistema para la liberación controlada de morfina. |
CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
MX356111B (es) | 2012-04-18 | 2018-05-15 | SpecGx LLC | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. |
JP6255474B2 (ja) | 2013-03-15 | 2017-12-27 | マリンクロッド エルエルシー | 機能的割線を有する即時放出用の乱用抑止性固体剤形 |
EP2967006A4 (en) | 2013-03-15 | 2016-12-28 | Pentair Water Pool & Spa Inc | METHOD FOR REGULATING ENERGY CONSUMPTION IN AQUACULTURE SYSTEMS |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
WO2017139106A1 (en) | 2016-02-08 | 2017-08-17 | Mallinckrodt Llc | Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties |
JP2019507783A (ja) * | 2016-03-09 | 2019-03-22 | エムダブリュ エンキャップ リミテッド | 乱用防止医薬製剤 |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
BR112019024708A2 (pt) | 2017-06-14 | 2020-06-09 | SpecGx LLC | composições farmacêuticas de liberação prolongada retardada |
EP3658121A1 (en) * | 2017-07-27 | 2020-06-03 | Inheris Biopharma, Inc. | Oral tablet formulations |
EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
CN114184718A (zh) * | 2021-12-09 | 2022-03-15 | 北京华素制药股份有限公司 | 一种防滥用制剂盐酸羟考酮缓释片主药成分的提取方法 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2211485A (en) | 1940-08-13 | Effervescent acetyl salicylic acid | ||
JPS537495B2 (es) | 1973-05-21 | 1978-03-18 | ||
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
US4678661A (en) | 1983-09-28 | 1987-07-07 | Gerhard Gergely | Effervescent composition and method of making same |
JPH0747532B2 (ja) | 1985-10-16 | 1995-05-24 | 花王株式会社 | 錠剤の製造方法 |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
US6071539A (en) | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
EA004032B1 (ru) | 1998-09-10 | 2003-12-25 | Нюкомед Данмарк А/С | Фармацевтические композиции лекарственных веществ с быстрым высвобождением |
US20080102121A1 (en) | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6340471B1 (en) | 1999-12-30 | 2002-01-22 | Alvin Kershman | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US6541025B1 (en) | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003032954A1 (en) | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040005359A1 (en) | 2002-06-27 | 2004-01-08 | Cheng Xiu Xiu | Controlled release oral dosage form |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
PL1842533T3 (pl) | 2003-08-06 | 2013-08-30 | Gruenenthal Gmbh | Postać aplikacyjna zabezpieczona przed nadużyciem |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004020220A1 (de) | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
CA2540984C (en) | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US20050165038A1 (en) | 2004-01-22 | 2005-07-28 | Maxwell Gordon | Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
WO2006002836A1 (de) * | 2004-07-01 | 2006-01-12 | Losan Pharma Gmbh | Brausezusammensetzungen von einschlafmitteln |
JP5175553B2 (ja) * | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
US8093408B2 (en) | 2005-06-21 | 2012-01-10 | The Company Wockhardt | Antidepressant oral pharmaceutical compositions |
ES2620293T3 (es) * | 2005-09-09 | 2017-06-28 | Paladin Labs Inc. | Composición de liberación sostenida de fármacos |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
ES2378573T3 (es) | 2006-03-16 | 2012-04-16 | Tris Pharma, Inc. | Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico |
US8173152B2 (en) | 2006-03-24 | 2012-05-08 | Auxilium Us Holdings, Llc | Stabilized compositions containing alkaline labile drugs |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
ES2300188B1 (es) | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
KR101612901B1 (ko) | 2007-03-02 | 2016-04-15 | 테이카 세이야쿠 가부시키가이샤 | 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제 |
EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
US20090124650A1 (en) | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
CA2923102C (en) | 2007-08-13 | 2019-10-15 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
US9254268B2 (en) | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
KR20100069685A (ko) * | 2007-10-16 | 2010-06-24 | 라보팜 인코포레이트 | 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물 |
BRPI0821732A2 (pt) | 2007-12-17 | 2015-06-16 | Labopharm Inc | Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada |
US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
ES2433008T3 (es) | 2008-05-07 | 2013-12-05 | Dainippon Sumitomo Pharma Co., Ltd. | Derivado de éster de ácido amino-1-carboxílico cíclico y composición farmacéutica que contiene el mismo |
WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
NZ592276A (en) | 2008-09-18 | 2012-12-21 | Purdue Pharma Lp | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID |
WO2010035273A2 (en) | 2008-09-29 | 2010-04-01 | Intec Pharma Ltd. | Novel gastroretentive delivery system |
CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
ES2560210T3 (es) | 2009-07-22 | 2016-02-17 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación |
JP5017516B2 (ja) | 2009-11-13 | 2012-09-05 | 株式会社ホットアルバム炭酸泉タブレット | 錠剤の製造方法 |
WO2011066980A2 (en) | 2009-12-04 | 2011-06-09 | Lars Holger Hermann | Oral dosage forms with reduced potential for drug abuse |
WO2011079074A1 (en) * | 2009-12-24 | 2011-06-30 | Acura Phamaceuticals, Inc. | Pharmaceutical compositions for deterring misuse, abuse, and diversion |
US20120321674A1 (en) | 2011-02-17 | 2012-12-20 | Michael Vachon | Technology for Preventing Abuse of Solid Dosage Forms |
EP2389867A1 (en) * | 2010-05-25 | 2011-11-30 | Theraclion SAS | Ultrasound coupling liquid and container |
BR112013021026A2 (pt) | 2011-02-17 | 2016-10-11 | Qrxpharma Ltd | tecnologia para prevenção de abuso de formas de dosagem sólidas |
US20150224097A1 (en) * | 2011-11-22 | 2015-08-13 | Watson Pharmaceuticals, Inc. | Immediate Release Abuse Deterrent Tablet |
EP2838536B1 (en) | 2012-04-18 | 2017-08-09 | Mallinckrodt LLC | Immediate release pharmaceutical compositions with abuse deterrent properties |
MX356111B (es) | 2012-04-18 | 2018-05-15 | SpecGx LLC | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. |
JP6255474B2 (ja) | 2013-03-15 | 2017-12-27 | マリンクロッド エルエルシー | 機能的割線を有する即時放出用の乱用抑止性固体剤形 |
-
2014
- 2014-03-14 JP JP2016502357A patent/JP6255474B2/ja active Active
- 2014-03-14 EP EP14722867.0A patent/EP2968182B8/en active Active
- 2014-03-14 US US14/211,307 patent/US9301918B2/en active Active
- 2014-03-14 PL PL14722867T patent/PL2968182T3/pl unknown
- 2014-03-14 BR BR112015021002A patent/BR112015021002B8/pt active IP Right Grant
- 2014-03-14 ES ES14722867.0T patent/ES2681952T3/es active Active
- 2014-03-14 MX MX2015012060A patent/MX363844B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027176 patent/WO2014152296A1/en active Application Filing
- 2014-03-14 CA CA2901802A patent/CA2901802C/en active Active
-
2015
- 2015-08-30 IL IL240914A patent/IL240914B/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11517521B2 (en) | 2014-07-03 | 2022-12-06 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
US11583493B2 (en) | 2014-07-03 | 2023-02-21 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
US11617712B2 (en) | 2014-07-03 | 2023-04-04 | SpecGx LLC | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides |
US11478426B2 (en) | 2018-09-25 | 2022-10-25 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Also Published As
Publication number | Publication date |
---|---|
EP2968182B1 (en) | 2018-05-09 |
CA2901802C (en) | 2021-03-02 |
EP2968182A1 (en) | 2016-01-20 |
US9301918B2 (en) | 2016-04-05 |
MX363844B (es) | 2019-04-05 |
JP2016517424A (ja) | 2016-06-16 |
JP6255474B2 (ja) | 2017-12-27 |
BR112015021002B1 (pt) | 2023-01-31 |
PL2968182T3 (pl) | 2018-10-31 |
WO2014152296A1 (en) | 2014-09-25 |
US20140271849A1 (en) | 2014-09-18 |
BR112015021002A2 (pt) | 2017-07-18 |
IL240914A0 (en) | 2015-10-29 |
CA2901802A1 (en) | 2014-09-25 |
EP2968182B8 (en) | 2018-07-25 |
IL240914B (en) | 2020-03-31 |
BR112015021002B8 (pt) | 2023-03-28 |
ES2681952T3 (es) | 2018-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015012060A (es) | Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional. | |
HK1256995A1 (zh) | 藥物輸送設備、系統和方法中的阻塞解決方案 | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
MX2014011815A (es) | Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso. | |
WO2013173789A3 (en) | Antisense oligonucleotide compositions | |
HK1215666A1 (zh) | 藥劑儲存、分配和給藥系統與方法 | |
WO2015069773A8 (en) | Devices and methods for continuous drug delivery via the mouth | |
BR112015001465A2 (pt) | item tendo propriedades armazenamento e/ou descarga de líquido, em particular um curativo. | |
BR112014032422A2 (pt) | grânulos de copolímero em bloco hidrogenado, composição de resina de poliolefina, e, produto moldado dos mesmos. | |
MX2015000114A (es) | Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada. | |
ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
HK1205908A1 (en) | Vascular occlusion and drug delivery devices, systems, and methods | |
MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
CY1121852T1 (el) | Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
MX2017000041A (es) | Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos. | |
WO2014106825A3 (en) | Methods and devices for identifying improper medical reporting | |
EP2902429A4 (en) | ALIPHATIC POLYCARBONATE COPOLYMER HAVING A HIGH MOLECULAR WEIGHT, AND A PROCESS FOR PREPARING THE SAME | |
EP3320472A4 (en) | SYSTEMS AND METHOD FOR USE IN THE AUTHENTICATION OF PERSONS IN CONNECTION WITH PROVISION OF ACCESS TO PERSONS | |
HK1210597A1 (en) | Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome (cynara scolymus)(coffea spp.) (olea europaea) | |
EP2893924A4 (en) | MOLECULAR ASSEMBLY USING A BRANCHED AMPHIPHILE BLOCK POLYMER AND DRUG DELIVERY SYSTEM | |
EP3009140A4 (en) | COMPOSITION WITH POLYCANIC TRIBLOCK COPOLYMER, POLYANIONIC POLYMER AND BIOLOGICALLY ACTIVE PEPTIDE | |
WO2017079403A3 (en) | Polymeric nanoparticles | |
Puttawanchai | Traffic accident crisis in Thailand | |
UA101837C2 (ru) | Инъекционное средство с иммуностимулирующими и общеукрепляющими свойствами на основе меда |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: SPECGX LLC |
|
FG | Grant or registration |